🇺🇸 FDA
Patent

US 9315568

Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders

granted A61KA61K31/519A61K38/00

Quick answer

US patent 9315568 (Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders) held by ADHERON THERAPEUTICS, INC. expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ADHERON THERAPEUTICS, INC.
Grant date
Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/519, A61K38/00, A61K39/3955, A61K45/06